1. Home
  2. BLLN vs CHH Comparison

BLLN vs CHH Comparison

Compare BLLN & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$83.95

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo Choice Hotels International Inc.

CHH

Choice Hotels International Inc.

HOLD

Current Price

$107.44

Market Cap

4.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
CHH
Founded
2016
1939
Country
United States
United States
Employees
713
N/A
Industry
Medical Specialities
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.5B
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
BLLN
CHH
Price
$83.95
$107.44
Analyst Decision
Buy
Hold
Analyst Count
7
11
Target Price
$126.71
$114.30
AVG Volume (30 Days)
575.7K
604.7K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
0.98%
EPS Growth
N/A
27.42
EPS
N/A
0.44
Revenue
N/A
$1,596,793,000.00
Revenue This Year
$46.29
$66.74
Revenue Next Year
$30.14
$0.37
P/E Ratio
N/A
$242.11
Revenue Growth
N/A
0.75
52 Week Low
$61.96
$84.04
52 Week High
$138.70
$136.45

Technical Indicators

Market Signals
Indicator
BLLN
CHH
Relative Strength Index (RSI) 49.23 49.35
Support Level $79.33 $93.72
Resistance Level $97.36 $110.35
Average True Range (ATR) 8.45 4.18
MACD 0.37 -0.42
Stochastic Oscillator 35.65 44.44

Price Performance

Historical Comparison
BLLN
CHH

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About CHH Choice Hotels International Inc.

At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.

Share on Social Networks: